Overcoming Barriers In Cell-Based Cancer Therapy

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...
Clinical Trials Arena on MSN

ImmunityBio’s allogeneic CD19 cell therapy shows complete response beyond 15 months

ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.
Becker's Hospital Review

FDA fast-tracks novel Parkinson’s cell therapy

FDA fast-tracks novel Parkinson’s cell therapy NouvNeu001, advancing treatment for dopaminergic neuron loss and motor ...
CURE

FDA Grants Breakthrough Designation to Sofi-cel for Relapsed/Refractory T-Cell ALL/LBL

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Seeking Alpha

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the ...

Orca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that new clinical data will be presented in two oral ...
Targeted Oncology

FDA Grants Breakthrough Therapy Designation to Sofi-Cel for R/R T-ALL/LBL

The FDA has granted breakthrough therapy designation (BTD) to soficabtagene geleucel (sofi-cel; WU-CART-007) for the ...
Business Wire

Orca Bio Announces $250M in Aggregate Financing in Preparation for Potential Commercialization

Series F, closed in December 2025, builds on recent financing activity to support launch readiness leading up to the Orca-T ® PDUFA date of April 6, 2026 Funding also enables pipeline advancements ...
MarketWatch

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

The MarketWatch News Department was not involved in the creation of this content. BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, ...

Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States

Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot ...
Nasdaq

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its ...